Current Metabolomics
Title:Meet Our Editorial Board Member
Volume: 5 Issue: 1
Author(s): Daniel Raftery
Affiliation:
Export Options
About this article
Cite this article as:
Raftery Daniel, Meet Our Editorial Board Member, Current Metabolomics 2017; 5 (1) . https://dx.doi.org/10.2174/2213235X0501170125190555
DOI https://dx.doi.org/10.2174/2213235X0501170125190555 |
Print ISSN 2213-235X |
Publisher Name Bentham Science Publisher |
Online ISSN 2213-2368 |
26
Related Articles
-
The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Benzoin Schiff Bases: Design, Synthesis, and Biological Evaluation as Potential Antitumor Agents
Medicinal Chemistry Has the Two Week Rule Improved Cancer Detection Rates for Gastrointestinal Cancers? A Systematic Literature Review
Current Cancer Therapy Reviews Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Current Drug Targets The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Current Drug Discovery Technologies Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Editorial (Thematic Issue: Genomic Applications to Various Biological Questions)
Current Genomics Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Meet Our Editor-in-Chief
Current Cancer Drug Targets Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward
Current Pharmacogenomics and Personalized Medicine The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology